{"schema_version":"secwatch.filing_event.v1","accession":"0001380106-23-000004","form_type":"8-K","ticker":"RPID","cik":"0001380106","company_name":"RAPID MICRO BIOSYSTEMS, INC.","filed_at":"2023-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.692381+00:00","generated_at":"2026-06-20T16:29:37.310771+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Rapid Micro Biosystems prelim FY2022 revenue $17.0-17.2M; Q4 $4.2-4.4M; cash $140M","bullets":["FY2022 commercial revenue expected $17.0-17.2M; Q4 revenue $4.2-4.4M, in line with expectations.","Placed 9 new Growth Direct systems and completed validation of 19 systems in FY2022.","Ended 2022 with ~$140M cash and investments, providing runway at least into 2026.","Added new global Top 20 pharma customer in U.S. and large pharma customer in Japan.","Launched RMBNucleus Mold Alarm software; to present at J.P. Morgan Healthcare Conference Jan 12."],"urls":{"canonical":"https://secwatch.observer/filing/0001380106-23-000004","json":"https://secwatch.observer/filing/0001380106-23-000004.json","markdown":"https://secwatch.observer/filing/0001380106-23-000004.md","text":"https://secwatch.observer/filing/0001380106-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000004/0001380106-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000004/rpid-20230111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T16:29:37.310771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6cad686e77e30cfd9722e009216f0d69c9dd65e6","claim":"RAPID MICRO BIOSYSTEMS, INC. reported preliminary financial results for fourth quarter and fiscal year ended December 31, 2022.","evidence_excerpt":"On January 11, 2023, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue results for its fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1380106/000138010623000004/0001380106-23-000004-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2022"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}